Skip to main content

Table 6 MMRM and LOCF_ANCOVA analyses of VAS overall pain severity in Studies 1 and 2.

From: The efficacy of duloxetine: A comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials

   STUDY 1 STUDY 2
MMRM
THERAPY Week N Mean change Std.error p-value N Mean change Std.error p-value
DULOX 1 120 -2.69 1.97 .181 121 -2.02 1.89 .157
PLACEBO 1 113 1.04 2.04   134 1.38 1.79  
DULOX 2 113 -8.20 1.87 .003 108 -6.95 2.04 .003
PLACEBO 2 108 -0.42 1.93   127 0.91 1.90  
DULOX 3 105 -10.46 1.95 .005 106 -9.81 1.90 < .001
PLACEBO 3 101 -2.56 2.01   119 -1.59 1.78  
DULOX 5 99 -8.68 2.20 .028 95 -9.70 2.05 .011
PLACEBO 5 99 -1.85 2.24   108 -2.92 1.92  
DULOX 7 91 -10.25 2.34 .016 87 -8.91 2.12 .254
PLACEBO 7 92 -2.26 2.38   94 -5.76 2.01  
DULOX 9 83 -8.68 2.18 .055 80 -10.05 2.24 .135
PLACEBO 9 88 -2.80 2.20   88 -5.65 2.12  
LOCF_ANCOVA
DULOX LOCF_ANCOVA 121 -8.31 2.09 .019 121 -10.39 2.05 .037
PLACEBO LOCF_ANCOVA 114 -1.40 2.18   134 -5.22 1.94